

REMARKS/ARGUMENTS

With this response, claims 1-25 are pending. In response to the present restriction requirement, Applicants elect to prosecute Group IV, claims 7-8, 11-12, and 22-23, drawn to a method of treating a bacterial infection in a subject, comprising administering a therapeutically effective amount of an anti-bacterial phage.

According to the Office Action the invention of Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the claims lack the same or corresponding special technical features for allegedly failing to make a contribution over the prior art. The Office Action alleges that the special technical feature is a host production cell.


Applicants traverse restriction of the claims. In particular, groups I-V are all directed to defined-dose therapeutic phage, methods of making the defined-dose phage, and methods of using the defined-dose phage. The Office Action does not include reasoning for the selection of a host bacterium as a special technical feature or for restriction of these claim groups. Therefore, Applicants respectfully traverse the rejection.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 206-467-9600.

Respectfully submitted,



Beth L. Kelly
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 206-467-9600
Fax: 415-576-0300
Attachments
BLK:blk
61427467 v1